	US 12,351,639 B2
	Anti-CD30 antibodies
Jeffrey A. Medin, Shorewood, WI (US); Mary L Faber, New Berlin, WI (US); Everett R. Tate, Greendale, WI (US); and Robyn A. A. Oldham, Milwaukee, WI (US)
Assigned to The Medical College of Wisconsin, Inc., Milwaukee, WI (US); and University of Virginia Patent Foundation, Charlottesville, VA (US)
Filed by Medical College of Wisconsin, Inc., Milwaukee, WI (US); and University of Virginia Patent Foundation, Charlottesville, VA (US)
Filed on Feb. 2, 2023, as Appl. No. 18/163,667.
Application 18/163,667 is a continuation of application No. 16/580,483, filed on Sep. 24, 2019, granted, now 11,584,799.
Claims priority of provisional application 62/735,508, filed on Sep. 24, 2018.
Prior Publication US 2023/0235071 A1, Jul. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07K 14/725 (2006.01); C07K 16/46 (2006.01); C07K 19/00 (2006.01); C07K 14/705 (2006.01)

CPC C07K 16/2878 (2013.01) [A61K 39/3955 (2013.01); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 14/7051 (2013.01); C07K 16/462 (2013.01); C07K 19/00 (2013.01); C07K 14/70578 (2013.01); C07K 2317/24 (2013.01); C07K 2317/41 (2013.01); C07K 2317/51 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01)]

43 Claims

1. An isolated antibody or antigen binding fragment thereof capable of binding human CD30 comprising:

(a) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 2 or a sequence with at least 85% similarity to SEQ ID NO: 2, a CDRL2 region of SEQ ID NO: 3 or a sequence with at least 85% similarity to SEQ ID NO: 3, and a CDRL3 region of SEQ ID NO: 4 or a sequence with at least 85% similarity to SEQ ID NO: 4, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 6 or a sequence with at least 85% similarity to SEQ ID NO: 6, a CDRH2 region of SEQ ID NO:7 or a sequence with at least 85% similarity to SEQ ID NO: 7, and a CDRH3 region of SEQ ID NO: 8 or a sequence with at least 85% similarity to SEQ ID NO: 8;

(b) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 10 or a sequence with at least 85% similarity to SEQ ID NO: 10, a CDRL2 region of SEQ ID NO: 11 or a sequence with at least 85% similarity to SEQ ID NO: 11, and a CDRL3 region of SEQ ID NO: 12 or a sequence with at least 85% similarity to SEQ ID NO: 12, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 14 or a sequence with at least 85% similarity to SEQ ID NO: 14, a CDRH2 region of SEQ ID NO: 15 or a sequence with at least 85% similarity to SEQ ID NO: 15, and a CDRH3 region of GAY or a sequence with at least 85% similarity to GAY;

(c) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 18 or a sequence with at least 85% similarity to SEQ ID NO: 18, a CDRL2 region of SEQ ID NO: 19 or a sequence with at least 85% similarity to SEQ ID NO: 19, and a CDRL3 region of SEQ ID NO: 20 or a sequence with at least 85% similarity to SEQ ID NO: 20, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 22 or a sequence with at least 85% similarity to SEQ ID NO: 22, a CDRH2 region of SEQ ID NO: 23 or a sequence with at least 85% similarity to SEQ ID NO: 23, and a CDRH3 region of SEQ ID NO: 24 or a sequence with at least 85% similarity to SEQ ID NO: 24;

(d) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 26 or a sequence with at least 85% similarity to SEQ ID NO: 26, a CDRL2 region of SEQ ID NO: 27 or a sequence with at least 85% similarity to SEQ ID NO: 27, and a CDRL3 region of SEQ ID NO: 28 or a sequence with at least 85% similarity to SEQ ID NO: 28, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 30 or a sequence with at least 85% similarity to SEQ ID NO: 30, a CDRH2 region of SEQ ID NO: 31 or a sequence with at least 85% similarity to SEQ ID NO: 31, and a CDRH3 region of SEQ ID NO: 32 or a sequence with at least 85% similarity to SEQ ID NO: 32; or

(e) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 34 or a sequence with at least 85% similarity to SEQ ID NO: 34, a CDRL2 region of SEQ ID NO: 35 or a sequence with at least 85% similarity to SEQ ID NO: 35, and a CDRL3 region of SEQ ID NO: 36 or a sequence with at least 85% similarity to SEQ ID NO: 36, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 38 or a sequence with at least 85% similarity to SEQ ID NO: 38, a CDRH2 region of SEQ ID NO:39 or a sequence with at least 85% similarity to SEQ ID NO: 39, and a CDRH3 region of SEQ ID NO: 40 or a sequence with at least 85% similarity to SEQ ID NO: 40.